Gland Pharma Limited
GLAND
Kedudukan dalam Saham
#3299
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Harga Saham
$32.32
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$5.33B
Perubahan (1 hari)
-3.01%
Perubahan (1 tahun)
47.99%
Negara
IN
Perdagangan Gland Pharma Limited (GLAND)
Kategori
Healthcare
Hasil untuk Gland Pharma Limited (GLAND)
Hasil pada Jun 2026 TTM: $742.20M
Menurut laporan kewangan terkini daripada Gland Pharma Limited, hasil semasa syarikat (TTM) ialah $742.20M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $679.36M peningkatan berbanding hasil pada tahun 2023 iaitu $441.05M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Gland Pharma Limited dari 2017 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $742.20M | 13.02% |
| 2025 | $656.70M | -3.34% |
| 2024 | $679.36M | 54.03% |
| 2023 | $441.05M | -23.92% |
| 2022 | $579.73M | 22.55% |
| 2021 | $473.05M | 35.33% |
| 2020 | $349.54M | 18.74% |
| 2019 | $294.38M | 18.32% |
| 2018 | $248.80M | 9.08% |
| 2017 | $228.10M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 790.82% |
IN
|
